Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

84 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan C, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Epperla N, et al. Among authors: janakiram m. J Hematol Oncol. 2022 Jul 16;15(1):96. doi: 10.1186/s13045-022-01316-1. J Hematol Oncol. 2022. PMID: 35842643 Free PMC article.
Current and emerging therapies in primary myelofibrosis.
Ayyappan S, Janakiram M, Raghupathy R. Ayyappan S, et al. Among authors: janakiram m. Cardiovasc Hematol Disord Drug Targets. 2012 Sep;12(1):6-20. doi: 10.2174/187152912801823174. Cardiovasc Hematol Disord Drug Targets. 2012. PMID: 22746348 Review.
Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
Shastri A, Budhathoki A, Barta SK, Kornblum N, Derman O, Battini R, Raghupathy R, Verma AK, Frenette PS, Braunschweig I, Janakiram M. Shastri A, et al. Among authors: janakiram m. Am J Hematol. 2017 Oct;92(10):1047-1051. doi: 10.1002/ajh.24843. Epub 2017 Jul 29. Am J Hematol. 2017. PMID: 28675459 Free article.
Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.
Allred J, Bharucha K, Özütemiz C, He F, Janakiram M, Maakaron J, Carrier C, Grzywacz B, Bachanova V. Allred J, et al. Among authors: janakiram m. Bone Marrow Transplant. 2021 Mar;56(3):679-682. doi: 10.1038/s41409-020-01018-7. Epub 2020 Aug 6. Bone Marrow Transplant. 2021. PMID: 32764581 Free PMC article. No abstract available.
Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study.
Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Schuster SJ, et al. Among authors: janakiram m. Lancet Oncol. 2021 Oct;22(10):1403-1415. doi: 10.1016/S1470-2045(21)00375-2. Epub 2021 Sep 10. Lancet Oncol. 2021. PMID: 34516954 Clinical Trial.
Postibrutinib relapse outcomes for patients with marginal zone lymphoma.
Epperla N, Zhao Q, Chowdhury SM, Shea L, Moyo TK, Reddy N, Sheets J, Weiner DM, Geethakumari PR, Kandarpa M, Bruno XJ, Thomas C, Churnetski MC, Hsu A, Zurbriggen L, Tan XC, Lindsey K, Maakaron J, Caimi PF, Torka P, Bello C, Ayyappan S, Oh TS, Karmali R, Kim SH, Kress A, Kothari S, Sawalha Y, Christian B, David KA, Greenwell IB, Janakiram M, Kenkre VP, Olszewski AJ, Cohen JB, Palmisiano N, Umyarova E, Wilcox RA, Awan FT, Alderuccio JP, Barta SK, Grover NS, Ghosh N, Bartlett NL, Herrera AF, Shouse G. Epperla N, et al. Among authors: janakiram m. Blood Adv. 2023 Jan 10;7(1):88-91. doi: 10.1182/bloodadvances.2022008634. Blood Adv. 2023. PMID: 36269847 Free PMC article. No abstract available.
Nicotinamide enhances natural killer cell function and yields remissions in patients with non-Hodgkin lymphoma.
Cichocki F, Zhang B, Wu CY, Chiu E, Day A, O'Connor RS, Yackoubov D, Simantov R, McKenna DH, Cao Q, Defor TE, Janakiram M, Wangen R, Cayci Z, Snyder N, Kumar A, Grzywacz B, Hwang J, Geffen Y, Miller JS, Maakaron J, Bachanova V. Cichocki F, et al. Among authors: janakiram m. Sci Transl Med. 2023 Jul 19;15(705):eade3341. doi: 10.1126/scitranslmed.ade3341. Epub 2023 Jul 19. Sci Transl Med. 2023. PMID: 37467318 Free PMC article.
Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitis.
Abbasi A, Peeke S, Shah N, Mustafa J, Khatun F, Lombardo A, Abreu M, Elkind R, Fehn K, de Castro A, Wang Y, Derman O, Nelson R, Uehlinger J, Gritsman K, Sica RA, Kornblum N, Mantzaris I, Shastri A, Janakiram M, Goldfinger M, Verma A, Braunschweig I, Bachier-Rodriguez L. Abbasi A, et al. Among authors: janakiram m. J Hematol Oncol. 2020 Jan 3;13(1):1. doi: 10.1186/s13045-019-0838-y. J Hematol Oncol. 2020. PMID: 31900191 Free PMC article.
84 results